Skip to main content
  • Evolut PRO Shows Consistent Favorable Outcomes at 3 Years Post-TAVR – FORWARD PRO Study

    Transcatheter aortic valve replacement (TAVR) with the Evolut PRO valve demonstrated consistent favorable clinical and hemodynamic outcomes through 3 years post-implant, according to data from the FORWARD PRO post-market study.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details